These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Use of proliferation signal inhibitors in non-melanoma skin cancer following renal transplantation. de Fijter JW Nephrol Dial Transplant; 2007 May; 22 Suppl 1():i23-6. PubMed ID: 17456615 [TBL] [Abstract][Full Text] [Related]
4. Use of proliferation signal inhibitors in the management of post-transplant malignancies--clinical guidance. Campistol JM; Albanell J; Arns W; Boletis I; Dantal J; de Fijter JW; Mortensen SA; Neumayer HH; Øyen O; Pascual J; Pohanka E; Schena FP; Serón D; Sparacino V; Chapman JR Nephrol Dial Transplant; 2007 May; 22 Suppl 1():i36-41. PubMed ID: 17456617 [TBL] [Abstract][Full Text] [Related]
5. Sirolimus-induced remission of posttransplantation lymphoproliferative disorder. Cullis B; D'Souza R; McCullagh P; Harries S; Nicholls A; Lee R; Bingham C Am J Kidney Dis; 2006 May; 47(5):e67-72. PubMed ID: 16632009 [TBL] [Abstract][Full Text] [Related]
9. Is there a role for proliferation signal/mTOR inhibitors in the prevention and treatment of de novo malignancies after heart transplantation? Lessons learned from renal transplantation and oncology. Valantine H J Heart Lung Transplant; 2007 Jun; 26(6):557-64. PubMed ID: 17543777 [TBL] [Abstract][Full Text] [Related]
12. The role of proliferation signal inhibitors in post-transplant malignancies. Gutiérrez-Dalmau A; Campistol JM Nephrol Dial Transplant; 2007 May; 22 Suppl 1():i11-6. PubMed ID: 17360768 [TBL] [Abstract][Full Text] [Related]
13. Inhibition of mTOR by sirolimus induces remission of post-transplant lymphoproliferative disorders. Boratyńska M; Smolska D Transpl Int; 2008 Jun; 21(6):605-8. PubMed ID: 18282244 [No Abstract] [Full Text] [Related]
14. Late conversion to mammalian target of rapamycin inhibitor/proliferation signal inhibitors in kidney transplant patients: clinical experience in the last 5 years. Sola E; Lopez V; Gutierrez C; Cabello M; Burgos D; Molina MG; Hernandez D Transplant Proc; 2010 Oct; 42(8):2859-60. PubMed ID: 20970551 [TBL] [Abstract][Full Text] [Related]
15. Immunosuppressive TOR kinase inhibitor everolimus (RAD) suppresses growth of cells derived from posttransplant lymphoproliferative disorder at allograft-protecting doses. Majewski M; Korecka M; Joergensen J; Fields L; Kossev P; Schuler W; Shaw L; Wasik MA Transplantation; 2003 May; 75(10):1710-7. PubMed ID: 12777861 [TBL] [Abstract][Full Text] [Related]
16. Rituximab in association with rapamycin for post-transplant lymphoproliferative disease treatment. Garcia VD; Bonamigo Filho JL; Neumann J; Fogliatto L; Geiger AM; Garcia CD; Barros V; Keitel E; Bittar AE; Ferrera des Santos A; Roithmann S Transpl Int; 2003 Mar; 16(3):202-6. PubMed ID: 12664217 [TBL] [Abstract][Full Text] [Related]
17. Sirolimus for pediatric liver transplant recipients with post-transplant lymphoproliferative disease and hepatoblastoma. Jiménez-Rivera C; Avitzur Y; Fecteau AH; Jones N; Grant D; Ng VL Pediatr Transplant; 2004 Jun; 8(3):243-8. PubMed ID: 15176961 [TBL] [Abstract][Full Text] [Related]
18. Conversion to a proliferation signal inhibitor in a patient with coronary artery disease--a case report. Sparacino V; Calabrese S Nephrol Dial Transplant; 2006 Jul; 21 Suppl 3():iii34-7. PubMed ID: 16815856 [TBL] [Abstract][Full Text] [Related]
19. [Lymphoproliferative disorders after renal transplantation in a child]. Márquez U S; Peredo G MS; Vogel S A; Ibáñez A P Rev Med Chil; 2009 Mar; 137(3):405-10. PubMed ID: 19621184 [TBL] [Abstract][Full Text] [Related]